NGL Fine-Chem Ltd Stock Analysis

BSE: 524774 | NSE: NGLFINE | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 06-Dec-2022 18:01
1660.05 2.50 (0.15%)

DeciZen - Make an Informed Decision on NGL Fine-Chem

Overall Rating

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

NGL Fine-Chem Price Chart

P/E Ratio (SA) :
42.34
Market Cap :
1,024 Cr.
52-wk low :
1,387
52-wk high :
2,935
Bole Toh?

1. Is NGL Fine-Chem Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that NGL Fine-Chem Ltd is a average quality company.

2. Is NGL Fine-Chem Ltd undervalued or overvalued?

The key valuation ratios of NGL Fine-Chem Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is NGL Fine-Chem Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of NGL Fine-Chem Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of NGL Fine-Chem:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
NGL Fine-Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 12.8%16.5%18.5%23.9%21.1%14.1%18.1%9.7%37.2%26.2%-
Value Creation Index -0.10.20.30.70.500.3-0.31.70.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 55.678.988.396.399.7114153152258319287
YoY Gr. Rt. %-41.9%12%9%3.6%14%34.8%-0.7%69.7%23.4%-
Adj EPS 4.78.111.318.522.918.62916.688.184.639.2
YoY Gr. Rt. %-72.1%38.9%63.1%24.2%-18.9%56%-42.7%430%-4%-
BVPS (₹) 32.439.753.171.696.2116.6149.1163.8251.6334.4341.3
Adj Net Profit 2.95711.414.211.517.910.354.552.324
Cash Flow from Ops. 0-0.37.58.49.922.48.919.626.612.7-
Debt/CF from Ops. -567.8-56.21.81.72.31.23.11.40.62.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 21.4%26.2%27.7%23.4%
Adj EPS 37.8%29.8%42.9%-4%
BVPS 29.628.330.932.9
Share Price 61.2% 33.6% 59.1% -35.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 15.722.624.429.627.317.521.810.642.428.911.6
Op. Profit Mgn % 13.614.316.922.825.61921.115.229.820.79.1
Net Profit Mgn % 5.36.47.911.814.210.111.76.821.116.48.4
Debt to Equity 0.70.70.40.30.40.40.30.30.10.20
Working Cap Days 147138152160187198167184132166218
Cash Conv. Cycle 59626574816555794974137

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 27.66%

Net Profit is growing at healthy rate in last 3 years 42.87%

Return on Equity has declined versus last 3 years average to 11.60%

Sales growth is not so good in last 4 quarters at -3.41%

Latest Financials - NGL Fine-Chem Ltd.

Standalone Consolidated
TTM EPS (₹) 39.2 35.6
TTM Sales (₹ Cr.) 287 298
BVPS (₹.) 341.3 334.8
Reserves (₹ Cr.) 208 204
P/BV 4.86 4.96
PE 42.34 46.63
From the Market
52 Week Low / High (₹) 1387.00 / 2935.00
All Time Low / High (₹) 0.40 / 3789.45
Market Cap (₹ Cr.) 1,024
Equity (₹ Cr.) 3.1
Face Value (₹) 5
Industry PE 37.7

Management X-Ray of NGL Fine-Chem :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of NGL Fine-Chem

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

NGL Fine-Chem Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of NGL Fine-Chem on 06-Dec-2022 18:01 is : 1,660.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Dec-2022 18:01 the market cap of NGL Fine-Chem stood at ₹ 1,024.
The latest PE ratio of NGL Fine-Chem as of 06-Dec-2022 18:01 is 42.34.
The latest PB ratio of NGL Fine-Chem as of 06-Dec-2022 18:01 is 4.86
The 52-week high of NGL Fine-Chem is ₹ 2,935 and the 52-week low is ₹ 1,387.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of NGL Fine-Chem is ₹ 287.5 ( Cr.) .

About NGL Fine-Chem Ltd

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now